Pyxis Oncology, Inc.
No enriched coverage for $PYXS in the last 7 days.
No SEC Form 4 filings for $PYXS in the last 30 days.
See all $PYXS insider activity →Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of pat
Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 pyxs-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND AMONG PYXIS ONCOLOGY, INC., AND THE PURCHASERS AS SET FORTH HEREIN June 30, 2026 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Securities 6 2.1 Purchase and Sale 6 2.2 Closing
Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001782223 0001782223 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15,
Recent PYXS coverage spans financial news, corporate actions and earnings.
Near-term trading focus is balance-sheet runway and the timing of upcoming MICVO data readouts (Fall 2026 monotherapy, Q4 2026 combo).
The 8-K indicates a new equity/warrant financing, which can be dilutive and may pressure near-term valuation until deal terms and proceeds are digested.
Routine governance/annual-meeting outcomes; limited direct implications for near-term fundamentals.
The departure of the CEO may introduce short-term uncertainty but could also open opportunities for strategic realignment.
Pyxis Oncology's positive financial results and progress in clinical trials suggest potential upside, but valuation may already reflect optimism.
alphai scores every news story that mentions PYXS with an AI model for sentiment and relevance, and aggregates insider trades from Pyxis Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones Updated data from the MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC on track to be reported in Fall 2026; update to include detailed analyses of pat
5 min readPyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 pyxs-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND AMONG PYXIS ONCOLOGY, INC., AND THE PURCHASERS AS SET FORTH HEREIN June 30, 2026 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Securities 6 2.1 Purchase and Sale 6 2.2 Closing
6 min readPyxis Oncology, Inc. (PYXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001782223 0001782223 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15,
2 min readPyxis Oncology, Inc. (NASDAQ: PYXS) filed an amended Form 8-K/A report with the SEC, announcing the departure of its CEO, Lara Sullivan, M.D., effective February 2, 2026. The filing also details a Separation and General Release Agreement between the company and Dr. Sullivan. Investors are advised to monitor future announcements regarding new leadership and potential strategic changes.
3 min readPyxis Oncology reported its fourth quarter and full-year 2025 financial results, alongside a business update highlighting the completion of target enrollment for its Phase 1 monotherapy study of micvotabart pelidotin (MICVO) in R/M HNSCC. The company expects updated data from this study mid-2026, which will include results from modified weight-based dosing. Pyxis Oncology also announced leadership appointments and has a cash runway extending into the fourth quarter of 2026.
3 min readPyxis Oncology completed target enrollment in its Phase 1 monotherapy dose expansion study for MICVO in head and neck cancer and anticipates updated data mid-2026 for monotherapy and 2H26 for combination therapy. The company reported $68.3 million in cash, which is expected to fund operations into Q4 2026. Pyxis also announced the appointment of Thomas Civik as Interim CEO and completed an $11 million upfront royalty sale for Enzeshu rights.
2 min readPyxis Oncology (PYXS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2 min readInnovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.
4 min readBOSTON, Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Pyxis Oncology, Inc. ( Nasdaq: PYXS ) , a clinical-stage company developing next-generation antibody-drug conjugate ( 'ADC' ) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology's Compensation Committee of the Board of ...
2 min readIs it a good or bad thing when a stock experiences a golden cross technical event?
3 min read
